Another meta-analysis by Zenliker et al. [138] reassessed the known beneficial impact of SGLT-2 inhibitors on HF hospitalizations and cardiovascular mortality, as well as on renal disease progression, irrespective of previous atherosclerotic cardiovascular disease or a history of heart failure; the reduction in MACE was only apparent in patients with established cardiovascular disease. Here, SLC5A2 is linked to cardiovascular disorder.